Navigation Links
ConvaTec to Present at AdvaMed 2010: The MedTech Conference
Date:10/13/2010

SKILLMAN, N.J., Oct. 13 /PRNewswire/ -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced that its top executives have been asked to present at AdvaMed 2010: The MedTech Conference, the premier medical technology conference for CEOs, business executives, policy-makers, financiers, media and industry stakeholders from around the world.

Well known for innovative breakthroughs in the fields of ostomy and wound therapeutics, continence and critical care, and infusion devices, ConvaTec will highlight various products and technologies marketed by the Company in its booth in Innovation Alley. ConvaTec was selected as one of just six companies to display in Innovation Alley. The Company will also take part in panel discussions, and give a company presentation on October 19th at 10:10AM.

Dave Johnson, CEO will co-host the inaugural Wound Healing and Tissue Regeneration Sector MeetUp, which is scheduled on Tuesday, October 19th at 11:30AM.

In addition, Nino Pionati, President, Global Marketing and Business Development will take part in a panel discussion titled Medical Technologies in the Service of the Wounded Warrior also on Tuesday, October 19th, at 2:15PM.

ConvaTec is proud to be a co-sponsor for the Capitol Hill Reception on October 20th. The Capitol Hill Reception encourages important dialogue between industry officials and policy-makers who help to shape public policy on healthcare.

About ConvaTecConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key focus areas – Ostomy Care, Wound Therapeutics, Continence and Critical Care, and Infusion Devices – ConvaTec products support healthcare professionals from the hospital to the community health setting. From its operational headquarters in Skillman, New J
'/>"/>

SOURCE ConvaTec
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ConvaTec Expands AQUACEL® Dressing Product Line With Introduction of New Ribbon Dressing
2. New Data Supports ConvaTec Negative Pressure Wound Therapy
3. Hologic to Host Investor Presentation at RSNA 2010
4. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
5. Frost & Sullivan Global Product Line Strategy of the Year Award Presented to Xenemetrix
6. New Afatinib (BIBW 2992) Data in Non-Small Cell Lung Cancer Patients Presented at the 2010 ESMO Congress
7. Bacterin International Holdings, Inc. to Present at the 6th Annual Fall Growth Stock Conference Hosted by Security Research Associates, Inc.
8. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
9. CSA Medical Selected to Present at AdvaMed 2010: The MedTech Conference
10. UBM Medica Presents Diagnostic Imaging LIVE, a Virtual Conference for Radiologists and Imaging Professionals - Now Available On Demand
11. Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
(Date:10/20/2014)... MOUNTAIN VIEW, Calif. , Oct. 20, 2014 /PRNewswire/ ... field of interventional pulmonology, today announced completion of enrollment ... schedule.  The RENEW Clinical Study is the FDA-approved IDE ... treatment for severe emphysema. It was anticipated ... US in February 2013, would take until the end ...
(Date:10/20/2014)... Oct. 20, 2014  Indianapolis interventional medical device ... Toronto -based 3D visualization leader Synaptive ... Neurological Surgeons Annual Meeting that they have joined ... surgery. The collaboration is the first of its ... improve patient outcomes. NICO,s BrainPath® interventional access technology ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5
... , , ... ... Presented at American College of Cardiology Meeting,in Atlanta and Published in the Lancet , ... ...
... U.S. Cancer Centers Involved , ... , , ... ... HUNTINGTON BEACH, California and AMSTERDAM , ...
Cached Medicine Technology:Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 2Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 3Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 4Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 5Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 6Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 2Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 3Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 4Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 5
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter ... who quickly add weight and length may be showing a ... In adults, certain genes have been linked to increased ... gains in fat and lean muscle, the researchers said. ... and taller. By ages 2 and 3, however, these genes ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... crucial part of conventional in vitro fertilization (IVF) -- the ... take place in a device inside the vagina, new research ... that the device, called an INVOcell, might sharply cut costs ... make the technology more accessible to those who don,t live ...
(Date:10/20/2014)... 2014 The newly updated Worldwide Medical ... thousands of facts, figures and forecasts on the global ... sector forecast categories the Worldwide Medical Market Forecasts ... national views on the worldwide medical market to reveal ... gives you data for 2010-2019, covering each country market ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... City based non-profit organization that helps New Yorkers ... lasting, positive changes toward health, housing, recovery and ... who have transformed the local community through their ... Managing Director, Marc Shapses , has been ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ... platform to think outside the bra. She doesn’t try to ... raise awareness about women’s other lady parts. , "We have ... the color pink and everybody knows what you’re talking about,” ... it has not been won when it comes to gynecologic ...
Breaking Medicine News(10 mins):Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
... Disparities in Diabetes Prevention and Management Among Most ... Foundation (Foundation), the philanthropic arm of Merck & ... Alliance to Reduce Disparities in Diabetes (Alliance), a ... those populations most at risk for diabetes -- ...
... Diamonds and Jewels ... Jet Set Getaways ... Exclusive ... to Cure Paralysis BAL HARBOUR, Fla., Feb. 25 ... designers and the highest concentration of world-class jewelers and ... dazzling treasures for Destination Fashion 2009,s silent ...
... Discovery of brain area responsible for link could lead to ... -- The memories and emotions that people associate with ... a part of the brain where the wiring for memories ... study says. , The finding, published Feb. 24 in ...
... Medicine Featured March 7-12 in San Diego ... Interventional Radiology (SIR) will present the latest research ... bone cancer; herniated disks; peripheral arterial disease (PAD) ... its 34th Annual Scientific Meeting, March 7-12 at ...
... 24 states now reporting widespread activity, the nation,s infectious ... to educate their customers on when antibiotics are the ... good. , Several grocery store chains nationwide began offering ... to cold and flu season, despite the fact that ...
... itself Kurt Salmon Associates saysNEW YORK, Feb. 25 ... less on prescription drugs this year versus last ... to Kurt Salmon Associates, recent evaluation of more than ... a continued shift towards lower-cost generic drugs and an ...
Cached Medicine News:Health News:The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps 2Health News:The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps 3Health News:The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps 4Health News:The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps 5Health News:The Merck Company Foundation Launches Five-Year Effort to Close Healthcare Disparity Gaps 6Health News:Spectacular Ultra-Luxe Auction for Destination Fashion 2009, Presented by Stewart Rahr, Best of Bal Harbour's Brands Contribute More Than $250,000 Worth of Exclusive Items 2Health News:Spectacular Ultra-Luxe Auction for Destination Fashion 2009, Presented by Stewart Rahr, Best of Bal Harbour's Brands Contribute More Than $250,000 Worth of Exclusive Items 3Health News:Spectacular Ultra-Luxe Auction for Destination Fashion 2009, Presented by Stewart Rahr, Best of Bal Harbour's Brands Contribute More Than $250,000 Worth of Exclusive Items 4Health News:Why Music Triggers a Walk Down Memory Lane 2Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 2Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 3Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 4Health News:Society of Interventional Radiology Hosts 34th Annual Scientific Meeting 5Health News:Health experts urge supermarket pharmacies to 'get smart' about free antibiotics 2Health News:Consumers Spending Less on Prescription Drugs 2
... ReZoom intraocular lens is a second-generation ... patients with greater independence from glasses than ... provides a range of vision that monfocals ... Optics technology distributes light over five optic ...
... best potential for quality vision with ACRYSOF ... for spherical aberration by addressing the effects ... accomplished without increasing edge thickness. Human ... design that provides improved image quality.,MTF (measured ...
... FRx Defibrillator was designed to be as ... Defibrillator and shares many of its features, ... The Philips HeartStart Home Defibrillator is an ... for home use by untrained users. Although ...
Designed to meet the demanding requirements of scientific and laboratory,applications. Special cabinet incorporates industrial quality with a,heavy duty refrigeration system to maintain your valu...
Medicine Products: